Revvity Tops Q4 Targets, Guides 2026 Revenue and Profit Above Street Views
Revvity reported fourth-quarter results that outpaced analyst estimates and provided 2026 guidance for adjusted EPS and revenue that exceed consensus. Management highlighted durability in the diagnostics business even as academic research funding remains subdued, and pointed to broader improvements in the pharmaceutical market and reduced policy un…